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Primary fibroblasts from patients with the genetic disease Fanconi anemia, which are hypersensitive to
cross-linking agents, were used to screen a cDNA library for sequences involved in their abnormal cellular
response to a cross-linking challenge. By using library partition and microinjection of in vitro-transcribed
RNA, a cDNA clone, pSPHAR (S-phase response), which is able to correct the permanent repression of
semiconservative DNA synthesis rates characteristic of these cells, was isolated. Wild-type SPHAR mRNA is
expressed in all fibroblasts so far analyzed, including those of Fanconi anemia patients. Correction of the
abnormal response in these cells appears therefore to be due to overexpression after cDNA transfer rather than
to genetic complementation. The cDNA contains an open reading frame coding for a polypeptide of 7.5 kDa.
Rabbit antiserum directed against a SPHAR peptide detects a protein of 7.9 kDa in Western blots (immuno-
blots) of whole-cell extracts from proliferating, but not resting, fibroblasts. The deduced amino acid sequence
of SPHAR contains a motif found in the cyclins, and it is proposed that SPHAR acts within the injected cell
by interfering with the cyclin-controlled maintenance of S phase. In agreement with this proposal, normal cells
transfected with an antisense SPHAR expression vector have a significantly reduced rate of DNA synthesis
during S phase and a prolonged G2 phase, reflecting the need for postreplicative DNA processing before entry
into mitosis.
In the autosomal recessive genetic disease Fanconi anemia
(FA), the increased frequency of spontaneous chromosomal
aberrations (46), and particularly the aberrations induced by
treatment with polyfunctional alkylating agents, has led to the
suggestion that cells from these patients are deficient in the
repair of DNA interstrand cross-links (9). Indeed, unrepaired
cross-links are manifested as chromosome breaks even in mu-
tagen-treated normal cells if they proceed to mitosis (51).
However, the considerable clinical variability of FA is paral-
leled at the cellular level by a range of conflicting reports
regarding the capacity of FA cells to repair DNA, which may
partly be explained by genetic heterogeneity. We have previ-
ously used an immortalized, simian virus 40-transformed FA
fibroblast as a partner for somatic cell fusion experiments to
demonstrate that at least two different genes can lead to the
clinical picture of FA (68). Such fusion experiments have been
extended by Strathdee et al. (53), and they indicate that there
are at least four complementation groups in FA (A, B, C, and
D). Although the gene responsible for FA group C has been
cloned (54), its function is as yet unknown.
The remarkable clinical variability of symptoms even within
individual FA families (13) is generally attributed to modulat-
ing effects of the remaining genetic constitution. The implica-
tion is that other gene products influence the cellular processes
in which the FA genes are involved. The identification of one
or more of these phenotype-modulating genes might shed light
on the nature of this process, which as yet is still largely a
matter of speculation.
In the case of cells from several FA patients, persistence of
cross-links over 24 h could be clearly demonstrated (8, 16).
Cross-link persistence is often accompanied by an irreversible
repression of DNA synthesis rates (35). A reduction in DNA
synthesis arises by two interdependent mechanisms: firstly, the
passive reduction caused by a physical block to the replication
machinery, and secondly, the active inhibition of replicon ini-
tiation as a response to the presence of DNA lesions (17). The
latter effect requires a signal transduction pathway that links
the detection of lesions in DNA with the active regulation of
replicon initiation. There is evidence that the response of FA
cells, in terms of repression of DNA synthesis after cross-
linking treatment, correlates with the genetic complementation
group. Cells from group A, but not cells from groups B and D,
show permanent repression of DNA synthesis (4, 36). Cells
from group C have not yet been investigated.
Rather than the repair of DNA lesions, it may be the avoid-
ance of such lesions that is deficient in FA cells (44). Under
hypoxic conditions, cultured FA cells show a nearly normal
phenotype in terms of in vitro life span and cloning efficiency.
At elevated oxygen levels FA cells accumulate in the S and
G2/M phases. Either increased production of activated oxygen
species or a failure of cellular detoxification processes has been
suggested to be responsible for the chromosome damage in FA
cells. Joenje and Gille have proposed a model in which either
a mutant cross-link repair–DNA replication function in FA is
hypersensitive to the oxygen species 1O2 or an abnormally high
1O2 flux overwhelms the cell (23). Clearly these alternatives
can be accommodated by the genetic heterogeneity of FA, and
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they represent systems which could be influenced by a variety
of modulating gene products.
A diffusable factor has been repeatedly suggested to be
involved in FA, since cocultivation of normal fibroblasts with
FA fibroblasts can lead to a reduction in the clastogen sensi-
tivity of the latter (42). The nature of this factor is unknown;
however, abnormalities in the production of tumor necrosis
factor alpha and interleukin-6 in FA cells have been reported.
The cellular hypersensitivity of FA cells to cross-linking treat-
ments in vitro is corrected by addition of interleukin-6 to their
growth medium (43). The involvement of hematopoietic
growth factors in the basic defect of an inherited anemia, such
as FA, is highly suggestive.
One of the most well established and consistent character-
istics of FA cells is their disturbed cell cycle. In particular, their
G2 phase is unusually long, and many cells remain permanently
arrested within this phase (44, 47, 60). G2 arrest may reflect the
accumulation of DNA damage and the need to repair this
damage before mitosis. However, since cell cycle disturbance is
observed even without experimental mutagenic insult, it seems
likely that the cell cycle defect is independent of DNA repair
processes.
In an attempt to identify the FA gene, or modulating genes,
we screened cDNAs for their ability to correct the abnormal
response of FA group A cells in terms of DNA synthesis rates
after cross-linking. Correction can be achieved by microinjec-
tion of protein (14) or mRNA (3) from normal cells, parallel-
ing the earlier somatic cell fusion experiments. Correction by
microinjection of mRNA was restricted to an mRNA fraction
of 650 nucleotides in length (3). In order to isolate the single
correcting mRNA from this fraction, we constructed a cDNA
library from which RNA could be transcribed in vitro, and this
RNA was tested for its effect on FA cells after microinjection.
By partitioning of the library into sublibraries we have been
able to isolate a cDNA that codes for a small protein (SPHAR;
S-phase response) able to restore the rate of DNA synthesis
during S phase. The SPHAR sequence contains a motif found
in the cyclin family, and examination of its expression and role
in normal cells indicates that it is involved in the progression of
the cell cycle.
MATERIALS AND METHODS
Cell culture and microinjection. The FA fibroblast line FA1BER (laboratory
no. 1424) has been described previously (52). These cells belong to complemen-
tation group A (patient A, fibroblast line FA-A in reference 68), are deficient in
the removal of interstrand cross-links (16), and show permanently reduced DNA
synthesis rates after cross-linking (4). FA4BER (laboratory no. 3557) fibroblasts
also belong to complementation group A, and FA0BER fibroblasts belong to
complementation group non-A (patients B and C, respectively, in reference 68).
FA0BER cells show normal recovery of DNA synthesis after cross-linking (4).
FA8BER, FA9BER, and FA13BER are fibroblast cell cultures from FA patients
diagnosed by our institute. The FA fibroblast lines GM1746 and CA178 were
from the Institute for Medical Research, Camden, N.J., and E. Wunder (Hei-
delberg, Germany), respectively. Control fibroblasts, MATCON and LN9CON,
were obtained from skin biopsy samples from two healthy men. The FA group D
lymphoblastoid cell line HSC62 was kindly provided by Manuel Buchwald (Hos-
pital for Sick Children, Toronto, Canada).
The human cell line EJ30 was obtained from R. Johnson (University of
Cambridge, Cambridge, United Kingdom), and it is a pseudodiploid immortal
line derived from line EJ, which was established from a bladder carcinoma (21).
Fibroblasts were cultured in Eagle’s minimal essential medium with 10% fetal
calf serum and 10 mg of penicillin and streptomycin per ml. Cultures were
examined routinely for mycoplasmal contamination. Verification of cell identi-
ties was made by regular examination of DNA fingerprints by using synthetic
oligonucleotides (38). Cells were released from confluence by trypsin digestion
and seeded onto gridded coverslips 2 days before microinjection. The microin-
jection system has been described previously (3), and it was implemented by
using procedures originally described by Gra¨ssmann et al. (15). For each pool of
cDNA transcripts, approximately 200 cells were injected, and 30 to 40 of these
were in S phase at the time of the assay for DNA synthesis rates.
Cross-linking treatment and DNA synthesis assays. Microinjected cells and
control cells were treated in 0.5 mM 8-methoxypsoralen (8-MOP) with 3.9 kJ of
UVA per m2 as described previously (4). Control sham-irradiated cultures were
treated only with 8-MOP. DNA synthesis rates were measured at 12 h after
cross-linking by incubation for 30 min in [3H]thymidine at 12 kBq/ml followed by
fixation and autoradiography of the cells according to standard procedures.
Autoradiographs were examined microscopically, and the silver grains above cell
nuclei were scored. Distributions of grain counts per nucleus were compared as
cumulative proportional frequency plots and by using the Kolmogorov-Smirnov
nonparametric test for determination of significant differences (67).
For examination of DNA synthesis rates in larger cell populations, the assay
described in reference 7 was used. Briefly, 2 3 105 cells were plated in quadru-
plicate into 3-cm-diameter petri dishes, one of which contained a coverslip.
Newly synthesized DNA was labeled for 30 min by addition of [3H]thymidine (48
kBq/ml) to the medium. At the end of the incubation period, the cells were
washed and the pools of cytoplasmic [3H]thymidine in three cultures were ex-
tracted in cold 5% trichloroacetic acid (TCA). [3H]thymidine incorporated into
cellular DNA was then extracted overnight in 1 N NaOH. The TCA-soluble and
TCA-insoluble fractions were counted in a Beckman scintillation counter. DNA
synthesis rates were expressed as TCA-insoluble cpm/TCA-soluble cpm, thus
correcting for variations in cell numbers. The coverslip culture was processed for
autoradiography as detailed above, and 200 cells were scored for [3H]thymidine
incorporation; this provided a measure of the proportion of cells in S phase at the
time of labeling.
cDNA library construction and screening. The HeLa mRNA fraction, previ-
ously shown to correct the abnormal response of FA1BER fibroblasts (3), was
used for cDNA synthesis essentially according to the method of Gubler and
Hoffman (18) and our previously described strategy for cDNA cloning for mi-
croinjection (2). Briefly, first-strand cDNA was synthesized with Moloney murine
leukemia virus reverse transcriptase (Gibco-BRL, Karlsruhe, Germany) from 5
mg of mRNA fraction by using the oligonucleotide pCGGGCCCGCGGC
CGC(T)20 (primer 3) as a primer. The primer 3 oligonucleotide primes from the
poly(A) tail of the mRNA and, in addition, contains recognition sequences for
the NotI and ApaI restriction endonucleases. Second-strand cDNA was synthe-
sized with DNA polymerase I after RNase H digestion of the RNA. The cDNA
was blunted with T4 DNA polymerase and inserted into the SmaI site between
the phage T3 and T7 RNA polymerase promoters of pT7T3-U19 (Pharmacia,
Freiburg, Germany). Escherichia coliDH5-a cells were made competent (23 108
colonies per mg) by the method of Hanahan (19) and transformed with the
cDNA library. Colonies were grown on GeneScreen Plus nylon filters (Du Pont,
Bad Homburg, Germany), and replicas were made with the same material.
The screening methodology has been described previously (2). Briefly, bacteria
were washed from fragments of frozen replica filters and grown in 20-ml cultures.
Plasmid DNA was prepared and linearized by digestion with NotI—the site for
which is provided at the 39 ends of cDNA inserts by the oligonucleotide primer
used for first-strand cDNA synthesis. Capped in vitro transcripts were synthe-
sized by using phage T3 and T7 RNA polymerases as described previously (26).
After transcription, plasmid DNA was removed by DNase I digestion, and the
RNA was extracted and resuspended at approximately 200 ng/ml in 10 mM
Tris-HCl, pH 7.2, for analytical gel analysis and microinjection. After identifi-
cation of a complementing sublibrary, the appropriate frozen filter was removed
from storage at2708C and cut into pieces for the next round of injections. At the
final stages of screening, individual colonies were picked and grown on agar in
the wells of a microtiter plate; the final complementing clone was called
pSPHAR.
Subcloning and sequencing. T7 DNA polymerase and the kit from Pharmacia
were used for DNA sequencing. Subclones were constructed by using conve-
niently placed restriction enzyme sites: pSPHAR-M was constructed by MboII-
NotI digestion of pSPHAR, insert preparation, blunting, and insertion into
SmaI-cut pT7T3. Sequencing was performed with plasmid DNA or single-
stranded DNA produced from the f1 origin of pT7T3 clones after infection with
the phage M13 KO7.
RT-PCR. For amplification, RNA was extracted from fibroblast cultures by
using the miniprep method of Wilkinson (61). A 100-ng portion of total cellular
RNA was reverse transcribed with avian myeloblastosis virus reverse tran-
scriptase after being primed with either random hexanucleotides or primer 3
(described above). The reverse transcriptase products were diluted directly into
PCR buffer and amplified with either primer 1 (pCTCTGGGAAATGACTAG;
positions 227 to 243 in Fig. 3) and primer 2 (pGCTGTTCAAAAATGAGC
AGC; complementary to positions 432 to 413 in Fig. 3) or primer 1 and the
NotI-ApaI portion of primer 3. Primers were used at 0.15 mM, and amplification
was done for 35 cycles: 2 min at 558C for annealing and extension and 1 min at
958C. All reverse transcription PCR (RT-PCR) components were from Perkin-
Elmer. mRNA integrity was checked by RT-PCR with primers which amplify a
500-bp region from glyceraldehyde phosphate dehydrogenase cDNA under the
same conditions.
Isolation of SPHAR genomic clones. Restriction digestion and Southern blots
indicated that the SPHAR sequence is located on a 3.7-kbp TaqI fragment (data
not shown). In order to isolate a 59 genomic clone, we used PCR after adding a
polyadenine tail to the ends of the genomic TaqI fragments to provide a com-
plementary sequence for a nonspecific oligo(dT) primer. HeLa genomic DNA
was digested to completion with TaqI, and the products were extended at the 39
end in a reaction volume of 50 ml (100 mM K cacodylate [pH 7.2]–10 mM
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CoCl2–1 mM dithiothreitol) containing 3 pmol of the 39 ends, 1 nmol of dATP,
and 15 U of terminal deoxynucleotide transferase (Gibco-BRL). Incubation was
performed at 378C for 30 min. A 100-ng portion of A-tailed DNA was amplified
in a 100-ml solution (10 mM Tris-HCl [pH 8.3], 50 mM KCl, 1.5 mM MgCl2,
0.1% gelatin) with 200 mM each deoxynucleoside triphosphate and 0.15 mM
primer 4 (pCCTAGTCATTTCCCAGAG; complementary to positions 244 to
227 in Fig. 3) and primer 3 (described above), for 30 cycles of 558C for 1 min,
728C for 2 min, and 958C for 1 min. Samples (10 ml) of the products were
separated on a 1.5% agarose gel, denatured, transferred to Hybond-N nylon
membranes (Amersham, Braunschweig, Germany), and hybridized with a 59
SPHAR probe (positions 1 to 243 in Fig. 3). The 59-flank probe was produced by
PCR amplification of sequences between positions 1 and 243 of the clone
pSPHAR with primer 4 and T7 primer (pCTAATACGACTCACTAT), agarose
gel preparation of the amplified product, removal of vector sequences with
BamHI, and labeling with digoxigenin-dUTP by using the kit from Boehringer
(Mannheim, Germany). Hybridized probe was detected by using alkaline phos-
phatase-conjugated antidigoxigenin antibody (Boehringer) after reaction with
5-bromo-4-chloro-3-indolyl-phosphate and Nitro Blue Tetrazolium. The remain-
ing genomic PCR products were blunted by using T4 DNA polymerase and
phosphorylated in a 10-ml solution (50 mM Tris-HCl [pH 7.4], 10 mMMgCl2, 50
mM dithiothreitol) with 1 mM ATP and 0.5 U of T4 polynucleotide kinase for 60
min at 378C. The products were then ligated into the SmaI site of pT7T3
(Pharmacia) and transformed into E. coli DH5-a. Minipreps of colonies were
made, and the presence of the SPHAR insert was detected by hybridization with
the 59 probe described above. A positive clone, pSPHAR-G (1.2-kb insert), and
its two EcoRI subclones, pSPHAR-G7 (0.7 kb) and pSPHAR-G11 (0.5 kb), were
sequenced as described above.
Peptide synthesis, antiserum production and Western blots (immunoblots).
The SPHAR peptide, ILFQKVSEANSQTELL, was synthesized as an octameric
antigenic peptide on a branching lysine core as described by Posnett et al. (40).
The peptide was dissolved in phosphate-buffered saline and used to immunize a
New Zealand White rabbit with weekly boosters. After 3 weeks, serum was
collected every 2 weeks and tested in comparison to preimmunization serum for
specific recognition of the peptide, which was spotted onto nitrocellulose filters.
Sera were purified by affinity chromatography through protein A-agarose (Phar-
macia).
Cell extracts were prepared from fibroblast cultures by three freeze-thaw-
vortex cycles in 10 mM HEPES (N-2-hydroxyethylpiperazine-N9-2-ethanesul-
fonic acid; pH 7.9)–60 mM KCl–1 mM dithiothreitol–1 mM EDTA–4% Ficoll–1
mM phenylmethylsulfonyl fluoride–1 mM aprotinin–1 mM leupeptin (107 cells
per 100 ml) and loaded onto sodium dodecyl sulfate (SDS)–15% polyacrylamide
gels (28). Proteins were electroblotted onto nitrocellulose membranes, and the
membranes were blocked by incubation for 1 h at room temperature in TNTW
buffer (100 mM Tris-HCl [pH 7.5], 150 mM NaCl, 0.1% Tween 20) with 5%
dried milk powder. Membranes were then incubated for 1 h at room temperature
with serum or preimmunization serum diluted 1:4 to 1:20 with TNTW buffer.
Filters were washed twice with TNTW buffer for 15 min at room temperature
and then incubated with horseradish peroxidase-conjugated goat anti-rabbit im-
munoglobulin G (IgG; Amersham) for 1 h at room temperature. After the filters
were washed as described above, bound goat IgGs were detected by enhanced
chemiluminescense (Amersham). Some filters were stripped of antibody by in-
cubation for 30 min at 508C in 62.5 mM Tris-HCl (pH 8.0)–100 mM 2-mercap-
toethanol–2% SDS and reprobed with an actin-specific mouse monoclonal an-
tibody (Boehringer Mannheim).
SPHAR antisense expression vectors and transfection. A PCR product con-
taining the SPHAR open reading frame, 10 bp of the 59 untranslated region, and
8 bp of the 39 untranslated region was inserted behind the simian virus 40 early
promoter, and the T7 RNA polymerase promoter, in the eukaryotic expression
vector pSVExT7 (Fig. 7). The sense or antisense orientations of the inserts in
individual clones were confirmed by XmnI restriction analysis. The SPHAR
plasmids were cotransfected with pSV2-neo into exponentially growing EJ30
cells after complex formation with a cationic lipopolyamine mixture (1) (Trans-
fectam; IBF-Biotechnics). Transfectants were selected in 400 mg of G418 per ml
(Geneticin; Gibco), and individual clones were analyzed for sense or antisense
SPHAR expression by RT-PCR using primers 1 and 2 (described above) and a
primer complementary to the T7 RNA polymerase promoter.
Analysis of cell cycle kinetics. EJ30 sense and antisense SPHAR transfectants
were allowed to reach confluence, and then they were grown for 3 days in
minimal essential medium with 0.1% fetal calf serum. As a control, EJ30 cells
transfected with pSV2-neo only were similarly serum starved. The cells were then
released by trypsinization and plated onto petri dishes in minimal essential
medium with 10% fetal calf serum, 400 mg of G418 per ml, 0.6 3 1024 M
59-bromo-29-deoxyuridine, and 0.6 3 1024 M 29-deoxycytidine. Aliquots of cells
were harvested at various time points (3 3 105 cells at time zero) and frozen in
minimal essential medium with 10% fetal calf serum and 10% dimethyl sulfoxide
prior to analysis by flow cytometry. The analysis of cell cycle parameters by flow
cytometry has been described previously (39). Cells were stained first with Ho-
echst 33258 and then with ethidium bromide. The cells were then passed through
an ICP-22 arc lamp instrument interfaced via the Ahrens Cytometry Analysis
System (Hamburg, Germany) to an IBM AT computer. The intensity of the
ethidium bromide fluorescence reflected the amount of DNA and, therefore, the
passage of individual cells through the cell cycle. Simultaneous measurement of
of Hoechst fluorescence, which is quenched by incorporated bromodeoxyuridine,
allowed quantitation of the numbers of cells in each phase of three consecutive
cell cycles. Data were analyzed by using specialized software from Phoenix Flow
Systems (San Diego, Calif.).
Nucleotide sequence accession number. The sequence data reported here
appear in the EMBL, GenBank, and DDBJ nucleotide sequence databases
under accession number X82554.
RESULTS
Molecular cloning of SPHAR by functional expression.
FA1BER cells and cells from other FA complementation
group A patients have a permanently reduced DNA synthesis
rate after DNA-cross-linking treatment (4, 36). A cDNA li-
brary was constructed from an mRNA fraction previously
shown to correct FA1BER fibroblasts after microinjection (3).
Within this cDNA library of 55,000 recombinants, a sublibrary
of 6,000, in vitro-transcribed RNA from which increased the
DNA synthesis rate of microinjected FA1BER cells after treat-
ment with 8-MOP–UVA, was identified. In vitro RNA tran-
scripts from other sublibraries showed no effect in the assay.
Clones from the correcting sublibrary were further divided into
5 subgroups, and their effects in the cross-link repair assay
were measured after they were injected into FA1BER cells.
Figure 1A shows the results of one experiment in which
FA1BER cells were injected with RNA transcribed from these
sublibraries. The results are expressed as the DNA synthesis
rate of injected FA1BER fibroblasts in comparison to that of
sham-irradiated FA1BER cells (100% DNA synthesis) at 12 h
after an 8-MOP–UVA cross-linking challenge. Only one of the
subgroups (SL4.2) was able to correct the FA1BER response.
Figure 1B summarizes the remaining library partition steps.
However, the single cDNA clone, pSPHAR, still only partially
corrected the abnormal response. DNA synthesis was mea-
sured by determining the level of [3H]thymidine incorpora-
tion by quantitative autoradiography. The distributions
of grain counts for the populations of untreated, uninjected,
and SPHAR-injected FA1BER cells are shown in Fig. 2 as
cumulative proportional frequencies. The correction of the
FA1BER response by the cDNA clone pSPHAR was statisti-
cally significant (P, 0.05) by the two-sided Kolmogorov-Smir-
nov test (67).
Sequence analysis of pSPHAR. The sequence of the 641-bp
cDNA insert in pSPHAR is shown in Fig. 3. Examination of
the sequence indicates the presence of an open reading frame
of 192 bp coding for a protein of 63 amino acids. The ATG
start codon is preceded at position 23 by a purine; this is the
only agreement with the consensus sequence around start
codons (27). There are four other ATGs upstream from the
putative start codon; this is unusual, but not unique, for a
mammalian mRNA. The human DNA repair gene ERCC2 has
two upstream ATGs (59), and the recently identified oncogene
ect2 has no fewer than eight (33). The short open reading
frame in pSPHAR ends with a TGA stop codon followed by
175 bp of noncoding sequence. A classical polyadenylation
signal is located 15 bp upstream from the polyadenine tail.
The amino acid sequence of the translation product is indi-
cated below the nucleotide sequence in Fig. 3. The calculated
molecular weight of this polypeptide is 7,515. Secondary struc-
ture analysis performed by the method of Garnier et al. (11)
suggested that 60% of the polypeptide is in a helical structure
divided into three blocks by extended regions. A computer
search of the EMBL library indicated that the sequence is
nearly identical (96% identity) to the expressed sequence,
IB776, identified by single-pass sequencing of human brain
cDNAs (24). A closer examination of the SPHAR protein
sequence has revealed a motif found in region III of the so-
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called ‘‘cyclin box’’ of the large cyclin gene family. The align-
ment in Fig. 4 shows the positions of identical or similar amino
acids within this motif in SPHAR and 10 representative cyclins.
Altogether, 41 cyclins have been aligned (data not shown). The
closest similarity of SPHAR to a single cyclin group was found
with the D-type cyclins (59 to 64%). Remarkably, cyclin D1
showed 50% identity to SPHAR from position 1 to 14 of the
alignment. IME1, the most distant member of the cyclin fam-
ily, showed the highest level of similarity (also 50%) to a single
cyclin within this same region (45).
Cyclin motifs are found in several other proteins; protein
tyrosine phosphatases, for example, share a short region of
similarity to B-type cyclins in the N-terminal portion of the
cyclin box (10). The same region is missing in cdc25, the cdc2
tyrosine phosphatase, and the interaction between cyclin B and
cdc25 is postulated to provide in trans an activating domain
which in other protein tyrosine phosphatases functions in cis.
Genomic organization of the SPHAR sequence. Use of PCR
to amplify the open reading frame of SPHAR from human
genomic DNA produced a product of the same size as that
from the cDNA clone pSPHAR, indicating that the sequence
FIG. 1. cDNA library partition. (A) The DNA synthesis rate of psoralen-
UVA-treated FA1BER fibroblasts after microinjection with in vitro-transcribed
RNA from cDNA clones relative to that of untreated FA1BER cells (100%) is
shown. Sublibrary number 4 (SL4) contained 6,000 recombinants, and its five
sublibraries (SL4.1 through SL4.5) each contained 1,200 recombinants. CON,
control, uninjected psoralen-UVA-treated FA1BER cells. (B) The rates of DNA
synthesis in 8-MOP–UVA-treated FA1BER cells injected with in vitro-tran-
scribed RNA from sublibraries is shown (shaded columns) in comparison to
those of synthesis in uninjected cells (open columns) for each partition step.
Coarsely shaded columns represent the correcting sublibrary at each partition
step, and finely shaded columns represent the noncorrecting sublibraries at each
step. The numbers under the columns give the numbers of recombinants in the
correcting sublibrary. Each partition step was verified at least once by indepen-
dent injection of coded transcripts.
FIG. 2. Complementation of FA1BER cells by pSPHAR in vitro transcripts.
Cumulative proportional frequencies of grains per nucleus for FA1BER fibro-
blasts after microinjection of in vitro transcripts from the HeLa cDNA clone
pSPHAR. Dotted line, uninjected, 8-MOP–UVA-treated cells; dashed line, un-
injected and untreated cells; solid line, 8-MOP–UVA-treated cells injected with
SPHAR RNA transcripts. The value Dmax is used to measure the significance of
the shift in distributions as shown.
FIG. 3. Nucleotide and deduced amino acid sequences for the cDNA clone
SPHAR. The first nucleotide of the insert in pSPHAR is assigned to position 1.
Uppercase letters are the cDNA sequence, with the predicted polypeptide se-
quence given underneath. Lowercase letters are from the 59 genomic SPHAR
clone (the sequence shown represents only a small portion of the sequenced
DNA). The polyadenylation signal at position 582 is underlined. The asterisk at
position 180 indicates the first nucleotide of the deletion clone pSPHAR-M used
for sequencing. The underlined nucleotides in the genomic sequence represent
possible promoter structures. The underlined amino acids make up the motif
found in cyclin sequences.
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is not interrupted by an intron at the genomic level. The same
product was obtained with DNA from eight FA fibroblast or
lymphoblastoid cultures (data not shown). PCR with genomic
DNA was used to amplify and clone a longer 59 genomic
fragment containing the SPHAR sequence from human DNA.
Sequence analysis (sequence shown partially in Fig. 3) con-
firmed the colinearity of this sequence with the SPHAR cDNA
sequence. Three TATATT sequences were located 21, 35, and
44 bp upstream from the first base of the cDNA sequence. Zoo
blots have shown that SPHAR is conserved within the class
Mammalia (unpublished data).
SPHAR is expressed as a polyadenylated transcript in FA
and normal cells. Since the level of SPHARmRNA expression
is too low for detection on Northern (RNA) blots, reverse
transcription of mRNA, followed by PCR amplification with
SPHAR-specific primers, was used to examine the expression
of SPHAR mRNA in human fibroblasts. Since amplification of
intronless genes from mRNA is highly sensitive to DNA con-
tamination, reverse transcription was primed from the oli-
go(dT) portion of primer 3, and the same primer was used,
together with a primer specific for SPHAR, for amplification.
Products were separated on agarose gels, blotted, and hybrid-
ized to a labeled SPHAR probe for identification (Fig. 5A).
The coding sequence of SPHAR was clearly present in RNA
from both normal fibroblast lines tested.
cDNA synthesis was also primed by using hexanucleotides
before PCR with primers 1 and 2, which flank the SPHAR
open reading frame, as shown in Fig. 5B. Products were readily
detected from control fibroblast RNA, FA1BER and FA4BER
(complementation group A) RNA, and FA0BER (comple-
mentation group non-A) RNA in ethidium bromide-stained
gels. Products were again transferred to nylon membranes and
hybridized with a SPHAR probe to confirm that the amplified
product was indeed SPHAR (Fig. 5C). We have tested fibro-
blasts from one further group A patient and fibroblasts from
patients belonging to group B and group D and have found
SPHAR transcripts in these cells too (data not shown). Se-
quence analysis of the SPHAR open reading frame amplified
from the DNA of eight individuals (six FA patients and two
controls) has revealed the presence of only silent or conserva-
tive base changes in comparison to the pSPHAR sequence:
A250 to G (Lys-5 remains Lys) in one control DNA, A403 to G
(Ile-56 to Met) in FA0BER DNA, and T379 to A (Ile-48 re-
mains Ile) and A394 to G (Ser-53 remains Ser) in DNA from a
group D patient.
A 7.9-kDa protein is detected in human cell extracts by an
antiserum to SPHAR. Analysis of the SPHAR amino acid
sequence for antigenic determinants, according to the method
of Hopp and Woods (22), indicated a peak of hydrophilicity
around the sequence Lys-29–Glu-32. A polyclonal rabbit anti-
FIG. 4. A cyclin-related motif in SPHAR: sequence alignment of SPHAR
with a conserved region of various cyclins. The aligned region is part of cyclin
homology box III (30), and it includes the only invariant amino acid found in all
known cyclins (glutamic acid at position 3 of the alignment). Identical and similar
matches of these cyclins to SPHAR are highlighted by inverse text. Boxed
residues in SPHAR indicate similarity or identity in up to 50% of the cyclins;
SPHAR residues in inverse type indicate similary or identity in 50% or more of
the cyclins. Highly conserved positions (occupied by residues of one similarity
group only) are marked under the alignment by asterisks; note that SPHAR
shares five of these (bold asterisks). The similarity groups used were RHK,
ASTGP, IVLMFYWC, and EDQN. The sources of the sequences were as
follows: CYCD1, human D1-type cyclin (63); CYCD2, human D2-type cyclin P3
(65); CYCD3, human D3-type cyclin H34 (65); CYCC, human C-type cyclin (31);
CLB2, Saccharomyces cerevisiae B-type cyclin (55); CYCA, human A-type cyclin
(58); CYCE, human E-type cyclin (25); CLN3, Saccharomyces cerevisiae G1
cyclin (37); MCS2, Schizosaccharomyces pombe mitotic catastrophe suppressor 2
(34); and IME1, Saccharomyces cerevisiae inducer of meiosis 1 (45, 50).
FIG. 5. Analysis of SPHAR mRNA expression in fibroblasts. The diagram
shows the primers used for PCR amplification. (A) Two independent mRNA
preparations, from control fibroblast lines MATCON and LN9CON, were re-
verse transcribed with primer 3 and amplified with primers 1 and 3 in order to
exclude amplification of contaminating genomic DNA. PCR products were sep-
arated on a 1.5% agarose gel, transferred to nylon membranes, and hybridized
with a 32P-labeled probe for the SPHAR open reading frame. 1, amplification
after reverse transcription; 2, amplification without prior reverse transcription.
The minimum size of the expected product was 390 bp. (B) RNA from FA1BER,
FA0BER, and FA4BER fibroblasts and the control fibroblast line LN9CON was
transcribed with random hexanucleotides and SPHAR cDNA was amplified with
primers 1 and 2. Products were loaded onto a 2% agarose gel and visualized by
ethidium bromide staining. pSPHAR, product of PCR with primers 1 and 2 from
the plasmid clone pSPHAR; 1, amplification after reverse transcription; 2,
amplification without prior reverse transcription. The expected size of the prod-
uct was 209 bp. The weak signals from some samples without reverse transcrip-
tion were due to low-level contamination of these RNAs with genomic DNA. (C)
RT-PCR products with primers 1 and 2 from FA1BER and FA0BER fibroblasts
were separated on a 1.5% agarose gel, transferred to a nylon membrane, and
hybridized to a 32P-labeled probe for the SPHAR open reading frame. Other
details were as described for panel B.
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body, raised against a synthetic 16-amino-acid peptide span-
ning this putative antigenic determinant, detected a protein of
7.9 kDa on Western blots of extracts from normal human
fibroblasts (Fig. 6A). Antibody binding was attenuated by ex-
cess synthetic peptide, indicating congruence between the
amino acid sequence deduced from the cDNA and the immu-
nodetected protein. A 7.9-kDa protein was also detected in
extracts from FA cells, with no significant differences in levels
of expression (Fig. 6B). The SPHAR mRNA detected in nor-
mal and FA fibroblasts (Fig. 5) is indeed translated in vivo.
SPHAR was not detected in serum-starved cells as shown by
the Western blot in Fig. 6C. Serum stimulation of the cells is
followed by expression of SPHAR and entry into S phase, as
determined by flow cytometry. Proliferation-dependent ex-
pression of SPHAR was similarly found in primary diploid
fibroblasts (data not shown).
Cells expressing a SPHAR antisense RNA have reduced
DNA synthesis rates and a disturbed cell cycle. The physio-
logical role of SPHAR was investigated by constructing stable
transfectants expressing an antisense SPHAR RNA from a
strong viral promoter. Figure 7A shows the plasmid vector
utilized in these experiments. The production of plasmid-de-
rived SPHAR RNA was checked by RT-PCR, as shown in Fig.
7B for the antisense transfectant clone EJ30.SPHAR2.4. When
SPHAR primer 1 and a primer specific for the T7 RNA poly-
merase promoter were used, the PCR produced a product of
266 bp from antisense, but not sense, RNA. Examination of
SPHAR polypeptide levels on Western blots indicated that
there was a reduction in expression levels to about 70% in the
antisense clones (data not shown).
Three independent antisense clones were examined for their
rates of semiconservative DNA synthesis at 24 h after release
from serum starvation. DNA synthesis was measured by deter-
mining the level of incorporation of [3H]thymidine into DNA
and normalizing this to the overall quantity of [3H]thymidine
taken up by the cells; this normalization corrects for any vari-
ations in cell numbers (7). All three clones showed significantly
(P , 0.05) reduced DNA synthesis rates in comparison to
those of the controls, which were cells transfected with the
vector lacking SPHAR sequences (Fig. 8A). The reduction in
DNA synthesis rates was not due to a failure to enter S phase,
since comparable proportions of cells in all four cell lines were
in S phase at the time of DNA labeling (Fig. 8B). The rates of
DNA synthesis within the S-phase cells were clearly affected by
an artificial reduction in SPHAR protein levels. This could be
expected to have consequences for cell cycle progression, and
this possibility was examined for one antisense transfectant by
analysis of cell cycle kinetics.
When the passage of the antisense transfectant EJ30.
SPHAR2.1 through three successive cell cycles was monitored
by flow cytometry, a considerable accumulation of cells in G2
phase was observed. Figure 9 presents the data from cell cycle
analyses performed 72 h after serum stimulation of the syn-
chronized cells. As a further control, a transfectant expressing
sense SPHAR RNA, EJ30.SPHAR1.2, was also included
in this analysis. The total fractions of cells in the G1 and G2
phases (first, second, and third cycles) are shown as the SG1/
GF and SG2/GF ratios, where GF is the growth fraction (all
cells not in G0 phase). The ratios SG1/GF and SG2/GF are
FIG. 6. Immunodetection of SPHAR sequences in whole-cell extracts. (A)
Whole-cell extracts were prepared from normal human fibroblasts and separated
on an SDS–15% polyacrylamide gel. Proteins were electroblotted to a nitrocel-
lulose filter and incubated with either preimmune serum (diluted 1:10) or anti-
serum (diluted 1:10 in lane 2 and 1:60 in lanes 3 and 4) directed against the
SPHAR peptide, with or without addition of synthetic peptide, as indicated.
Bound rabbit IgGs were detected by goat anti-rabbit IgG conjugated to horse-
radish peroxidase and by chemiluminescence. The sizes of marker proteins are
shown at the left. The anti-SPHAR-peptide serum detected a protein of 7.9 kDa.
(B) Whole-cell extracts were prepared from EJ30 cells and fibroblasts from FA
patients and separated on an SDS–15% polyacrylamide gel. Proteins were elec-
troblotted to a nitrocellulose filter and incubated with rabbit antiserum directed
against the SPHAR peptide. The filter was subsequently stripped of antibody and
reincubated with an antiactin monoclonal antibody to allow semiquantification of
the SPHAR protein level. (C) Confluent EJ30 cells were arrested by serum
starvation and then were stimulated to proliferate by being plated in medium
with 10% fetal calf serum. At the various time points after stimulation indicated,
aliquots of cells were processed for flow cytometry or immunodetection with the
antiserum to SPHAR peptide and, after stripping, a monoclonal antibody di-
rected against actin. Only the appropriate areas of the electrotransferred 15%
acrylamide gel are shown. The numbers below the blots show the proportions of
cells in S phase as determined by measurement of ethidium bromide fluores-
cence by flow cytometry.
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thus proliferation-independent measurements which allow
comparison of anti-SPHAR cells and control cells. While the
proportions of cells in G1 were similar for all three cell lines,
significantly more of the cells expressing antisense SPHAR
were in G2 (P , 0.05).
DISCUSSION
SPHAR is not the basic defect in FA, but it is involved in its
cellular phenotype. SPHAR is a single-copy sequence con-
served throughout the class Mammalia and located on human
chromosome 8 (data to be published elsewhere). We attribute
the partial correction of the abnormal response of FA1BER
fibroblasts to a cross-linking challenge by SPHAR to overex-
pression, since the sequence is present and not mutated in
these cells. The SPHAR polypeptide increases the rate of
semiconservative DNA synthesis, which, in FA cells, is char-
acteristically irreversibly reduced after psoralen cross-linking.
The effect is specific, as shown by its isolation through library
partition: at each step, the correcting cDNA pool was identi-
fied among other pools taken from the same cDNA library.
We calculate that, at the concentration of RNA used (200
ng/ml), in the final stages of SPHAR isolation each cell re-
ceived 2 3 104 copies of the SPHAR transcript, leading to an
intracellular concentration several orders of magnitude above
the endogenous level. We have additional evidence that re-
moval of the long 59 untranslated flank from SPHAR tran-
scripts leads to a dramatic improvement in the efficiency of
translation in vitro; possibly, secondary structure assumed by
the RNA inhibits initiation. Posttranscriptional regulation via
its long 59 untranslated flank, which also contains several
ATGs, has also been reported for the cyclin IME1 (48).
Expression of an antisense SPHAR RNA in normal cells
leads to an approximately 40% increase in the time required to
traverse G2 phase, suggesting that SPHAR is necessary for
normal cell cycle progression. Indeed, SPHAR protein is de-
tected only in proliferating fibroblasts. G2-phase arrest is char-
acteristic for FA cells, and it probably reflects the requirement
to complete DNA repair and replication before mitosis. The
prolongation of G2 found for the antisense transfectants is
suggestive of a role for SPHAR protein in the preceding S
phase.
FIG. 7. Transfectants expressing antisense SPHAR RNA. (A) pSV-EX7 eu-
karyotic expression vector driving expression of an antisense SPHAR RNA from
the simian virus 40 early promoter. A blunted and phosphorylated PCR product
encoding the SPHAR open reading frame and 10 bp of the 59 UTR was inserted
into the EcoRV site of the vector. The orientation of clones was established by
XmnI restriction analysis. The sense (pSV-EX7.SPHAR1) and antisense (pSV-
EX7.SPHAR2) constructs were used for transfection of EJ30 cells. (B) RNA was
isolated from a G418-resistant EJ30 clone transfected with an antisense pSV-
EX7.SPHAR2 construct. The RNA was reverse transcribed, and the cDNA was
amplified as indicated with primers P1, P2, and T7 shown in panel A. Endoge-
nous and plasmid-coded SPHAR RNA yielded the expected 209-bp product with
primers 1 and 2; plasmid-coded antisense RNA yielded a 266-bp product with
primers T7 and 1. PCR with no previous reverse transcription yielded no prod-
ucts with any primer pair (data not shown).
FIG. 8. DNA synthesis rates in antisense SPHAR transfectants. (A) The bar
graph shows the incorporation of [3H]thymidine into DNA (TCA-insoluble frac-
tion) normalized to the cytoplasmic [3H]thymidine pool (TCA-soluble fraction)
for three independent antisense SPHAR transfectants (EJ30.SPHAR2.1, -2.2,
and -2.3; shaded columns) and EJ30 transfectants carrying the vector only with-
out SPHAR sequences (EJ30.SV0.2; open column)). Error bars show the stan-
dard deviations. (B) The proportions of cells in S phase in the experiment whose
results are shown in panel A, as determined by [3H]thymidine labeling, autora-
diography, and scoring of 200 cells for incorporation of label, are shown.
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SPHAR affects initiation and/or elongation of replicons. The
DNA synthesis assay used after microinjection of cDNA tran-
scripts measures the rates of DNA replication in individual
mitomycin-treated FA cells and then compares them as a pop-
ulation with those of other, untreated, cells. Since the propor-
tion of FA cells in S phase remains constant at the level of
damage applied, entry into S phase is not affected. The mea-
sured reduction in DNA synthesis rates was due to an effect in
those cells already committed to S phase, and it is this effect
which SPHAR is able to modulate.
Formally, two explanations for SPHAR’s effect remain: ei-
ther it leads to improved DNA repair and thus to increasing
replicon elongation and initiation rates, or the rate of replicon
initiation is increased despite the presence of unrepaired DNA
lesions. The level of correction observed in FA cells injected
with SPHAR is most compatible with the second explanation.
The fact that SPHAR expression is specific for proliferating
cells and that DNA synthesis and cell cycle progression are
disturbed in normal cells expressing antisense SPHAR, even
without mutagenic treatment, suggests that SPHAR functions
independently of DNA damage and repair. This function may
be in the regulation of replicon initiation within the replicating
cell.
Does SPHAR compete with the D-type cyclins? Although
SPHAR is much smaller than the true cyclins, the presence of
a cyclin-related motif suggests that its function may be allied to
that of the cyclins themselves. The cyclin sequence alignment
shown in Fig. 4 can be extended to the N terminus of SPHAR,
albeit with weak similarity. Interestingly, the position of the
first residue of SPHAR then corresponds exactly to the begin-
ning of the third exon of the yeast cyclin gene mcs2 (34). Since
exons often define the evolutionary borders of structural
and/or functional domains, SPHAR probably represents an
autonomous folding unit with a cyclin-related domain and,
presumably, function. The minimal cyclin A sequence required
for binding to, and activation of, cdc2 kinase resides in two
blocks within the cyclin box and spans residues 189 to 241 and
275 to 320 (29). The cyclin motif in SPHAR corresponds to
residues 293 to 314 of cyclin A and is thus within one of these
functional domains.
The inhibition of replicon initiation induced by DNA dam-
age might be mediated by cyclins. In the case of mutagen-
treated mammalian cells, there is evidence that it is the direct
interaction of the replication fork with DNA lesions which
triggers the altered regulation of cyclin B-p34cdc2 via the cdc25
kinase (32, 56). Since activated cyclin B-p34cdc2 is an absolute
prerequisite for mitosis, cell division is thus coupled to the
completion of DNA repair and replication via a signal trans-
duction pathway involving cyclin B.
A candidate cyclin for the control of DNA synthesis during
S phase is type D cyclin, to which the cyclin-like motif in
SPHAR shows the strongest similarity. The involvement of
D-type cyclins in S phase was first suggested by their broad
expression peak during G1 phase and S phase. Treatment of
quiescent diploid fibroblasts with platelet-derived growth fac-
tor or epidermal growth factor leads to DNA synthesis and
induction of D-type cyclin mRNA. However, the phorbol ester
12-O-tetradecanoylphorbol-13-acetate (TPA) induces D-type
cyclin but not DNA synthesis (62). While cyclin D is clearly
associated with DNA replication, its induction is not sufficient
for entry into S phase; this is in contrast to the case with cyclin
A, which is required for S-phase entry but not for S-phase
maintenance (5, 12, 69). The presence of a D-type cyclin-
related motif in SPHAR suggests that this protein might com-
pete for the same effectors and induce effects similar, or con-
trary, to those of cyclin D itself.
Immunoprecipitation experiments have demonstrated that
D-type cyclins are complexed with other proteins in the cell
(66). In the case of nontransformed cells, these proteins in-
clude the protein kinase subunits CDK2, CDK4, and CDK5; a
21-kDa universal cyclin-dependent kinase (CDK) inhibitor,
Cip1 (20); and, remarkably, proliferating-cell nuclear antigen
(PCNA). The last protein is an auxiliary protein of DNA poly-
merase d, and it is essential for both semiconservative DNA
synthesis and DNA synthesis during excision repair (41, 49). In
cells transformed to immortality by oncogenic viruses, only
binary complexes of cyclins and CDKs are observed. Since
Cip1 mRNA is upregulated after g irradiation via the tumor
suppressor p53 (6, 64), the quaternary complex of cyclin, p21,
PCNA, and CDK is clearly an intermediary in coupling detec-
tion of DNA damage to cell cycle control. Furthermore, p21 is
able to directly interact with PCNA and arrest DNA replica-
tion independently of cyclin and CDK (57). Several pathways
for modulating DNA synthesis as a response both to cell cycle
triggers and to environmental stress probably exist; it seems
likely that these mechanisms use both common and particular
components. We suggest that SPHAR, with its cyclin-like mo-
tif, is one such component.
Correction of one aspect of the FA group A phenotype by a
protein with a cyclin-like motif indicates that the process prob-
ably affected by homozygous mutation of the FA-A gene is cell
cycle control in response to environmental stress.
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